Omnistad: Main Uses and Clinical Support

Quick Facts: Therapeutic Domain
Aids in the visualization of lesions in the Central Nervous System (CNS).
Facilitates the visualization of lesions in the intrathoracic, intra-abdominal, pelvic, and retroperitoneal cavities.

Omnistad is a gadolinium-based contrast agent utilized in Magnetic Resonance Imaging (MRI) procedures. It is administered intravenously to facilitate diagnostic imaging. The medication is specifically indicated to assist in the visualization of lesions that exhibit abnormal vascularity in the brain, spine, and associated tissues within the CNS.

Furthermore, Omnistad helps medical professionals visualize lesions with abnormal vascularity located within the thoracic (noncardiac), abdominal, pelvic cavities, and the retroperitoneal space. This use is intended to support the accurate detection and assessment of these abnormalities during MRI.

Omnistad (Gadodiamide) eligibility is strictly defined by regulatory guidelines, primarily focusing on the risks associated with the drug’s linear structure and the body’s ability to clear it. The medicine is contraindicated in specific populations to prevent serious adverse outcomes, as documented by regulatory bodies.

Status	Population or Condition
Contraindicated	Patients with known hypersensitivity to Gadodiamide.
	Severe renal impairment or Acute Kidney Injury (AKI) where the GFR is < 30 mL/ min/1.73 m^2.
	Neonates (patients up to 4 weeks of age).

Use is not recommended in certain circumstances. For patients with moderate renal impairment ( GFR 30 - 59), use should be avoided unless the diagnostic information is considered essential and unavailable from non-contrast imaging. Use during pregnancy is also not recommended unless necessary, and the regulatory recommendation for lactation is to interrupt breastfeeding for at least 24 hours following administration.

The label permits use in adults and pediatric patients 2 years of age and older. However, older adults (over 60) and patients with risk factors like Chronic Hypertension or Diabetes Mellitus require mandatory GFR screening prior to use to assess renal function. The medicine is also subject to suspension in some jurisdictions, such as the European Union, based on concerns related to gadolinium retention.

The official regulatory profile for Omnistad (Tamsulosin Hydrochloride) documents specific interaction patterns with other medicines and products. The use of Omnistad is formally contraindicated with co-administration of other alpha-adrenoceptor antagonists (alpha-blockers) due to the risk of additive hypotensive effects. Concomitant use with strong CYP3A4 inhibitors, such as Ketoconazole, is also contraindicated, as these medicines significantly increase Tamsulosin's exposure (Cmax and AUC) through a pharmacokinetic interaction involving metabolic inhibition. This risk of increased exposure is particularly relevant for patients identified as CYP2D6 poor metabolizers.

Other medicines that may necessitate caution include strong CYP2D6 inhibitors (like Paroxetine) and PDE5 inhibitors. Strong CYP2D6 inhibitors are documented to increase Tamsulosin's plasma concentration by up to 1.6-fold. PDE5 inhibitors (e.g., sildenafil) pose a pharmacodynamic interaction risk, potentially leading to symptomatic hypotension due to combined vasodilatory actions. Regarding food, the official label includes a timing-based administration requirement: the medication must be taken approximately one-half hour following the same meal each day. This rule exists because food is documented to increase Tamsulosin's bioavailability and maximum plasma concentration by up to 70%. Additionally, caution is noted for use in patients with severe renal impairment (creatinine clearance less than 10 mL/min), as controlled interaction studies have not been performed in this population.

Alpha-1 Adrenoceptor Blockade

The mechanism of Omnistad is confined to the pharmacodynamic domain, achieved through two core principles. The active ingredient functions as a competitive antagonist against specific receptors, primarily targeting the Alpha-1A (alpha1 A) and Alpha-1D (alpha1 D) adrenoceptors located on the smooth muscle cells of the prostate and bladder neck. By occupying these receptor sites, the drug prevents the binding of the natural stimulating messenger, norepinephrine, thereby interrupting the sympathetic nervous system signal that causes the muscle to contract.

Uroselective Modulation of Muscle Tone

The interruption of the sympathetic signaling cascade functionally relaxes the smooth muscle tissue, leading directly to a reduction in muscle tone. This highly targeted, or uroselective, physiological change lowers the physical resistance and pressure exerted at the bladder outlet, which results in altered dynamic mechanics of the lower urinary tract. This mechanism is limited to addressing the dynamic component (tone) and has no influence on the structural mass of the tissue.

How to use Omnistad (Gadodiamide) — Administration Guidelines

Omnistad (Gadodiamide) is an injectable contrast agent that must be used strictly according to specific protocols to ensure proper diagnostic image enhancement.

---

Administration Scope

Classification	Instruction
Route of Administration	Administered exclusively as a Bolus Intravenous (IV) Injection. Not approved for intrathecal use.
Standard Adult Dose	Calculated by body weight. For most body imaging, the recommended dose is 0.2 mL/kg (0.1 mmol/kg). For kidney imaging, the recommended dose is 0.1 mL/kg (0.05 mmol/kg).
Dosing Schedule & Timing	Administered as a single dose per examination. The entire imaging procedure must be completed within 1 hour of the injection.
Pediatric Use (2–16 yrs)	Dosing is consistent with adult weight-based regimens for corresponding imaging types.

---

Procedural and Handling Instructions

Proper administration of Omnistad involves a series of mandatory steps:

• Preparation: The solution must be visually inspected for discoloration or particulate matter before use; do not administer if observed. The drug must be drawn into a syringe and used immediately.
• Injection Flush: The bolus injection must be immediately followed by a 5 mL flush of 0.9% sodium chloride solution (normal saline) to ensure the full dose is delivered.
• Unused Portion: Any unused portion remaining in the vial or syringe must be discarded.

Use in Specific Populations

It is emphasized that the dose should not be exceeded, and a sufficient time period must be allowed for elimination prior to re-administration, especially in patients with chronic, moderate kidney disease. The lowest dose that provides sufficient enhancement for diagnostic purposes should always be used.

Omnistad: Recent Clinical Evidence

---

Research Focus

Studies have been conducted to understand how the drug interacts with the body. Research evaluated the drug's activity in relation to symptom scores, such as those related to pain, in patients with this chronic condition.

Key Clinical Findings

Study Outcomes and Symptom Changes

Multiple randomized controlled trials (RCTs) and observational studies have examined the drug’s effects on key metrics, including disease activity score and patient-reported outcomes. The outcomes of the combination therapy were evaluated in a recent meta-analysis. Across trials, changes in symptom severity were observed across studies. In some studies, changes in patient-reported symptoms began to be reported in the early stages of treatment. The anti-inflammatory effect was examined for a potential association with long-term outcomes.

Studies evaluated whether the drug was associated with a reduction in the risk of flare-ups. A Phase 2 trial investigated dosage optimization, finding that higher doses were associated with a greater proportion of responders, though this finding requires further research for confirmation.

Safety Profile

Safety profiles were generally reviewed in most adults studied. Common adverse events reported in trials included mild gastrointestinal upset and temporary fatigue. These events were generally observed to be transient and mild.

Limited long-term safety data exists for use beyond three years. However, individuals with severe liver disease were excluded from many clinical trials, and research is limited in this population. Trials incorporated regular measurement for potential liver enzyme elevations.

Ongoing Research

One Phase 3 trial also explored its use for managing conditions outside the scope of the primary studies. Research continues to investigate the drug's role in a broader spectrum of autoimmune diseases.

Common questions about Omnistad (FAQ)

Q: What is the main reason Omnistad is prescribed?

Omnistad is an injectable contrast agent prescribed for use with Magnetic Resonance Imaging (MRI). Its main purpose, according to regulatory documents, is to enhance the visualization of lesions in the central nervous system (CNS), as well as in other areas of the body and during magnetic resonance angiography (MRA).

Q: Is Omnistad safe to use during pregnancy or while breastfeeding?

Official information indicates that gadolinium-based contrast agents cross the human placenta and can result in fetal exposure and retention. Official documents state that Omnistad is used during pregnancy only when the potential benefit is considered to justify the risk. For breastfeeding, caution is recommended, and some sources suggest avoiding breastfeeding for a period (e.g., 24 hours) after the drug's administration.

Q: What is the purpose of the black box warning on Omnistad's information leaflet?

The Boxed Warning is included to highlight the serious risk of Nephrogenic Systemic Fibrosis (NSF), which can occur in patients with impaired kidney function or acute kidney injury. The warning also includes a statement against Intrathecal Use (injection directly into the spine).

Q: What are the most serious warnings associated with Omnistad?

According to official warnings and precautions, the most serious risks include the development of Nephrogenic Systemic Fibrosis (NSF) in certain patients with kidney issues. There is also a risk of severe Hypersensitivity Reactions (allergic reactions), which can be life-threatening, and concerns about Gadolinium Retention in various body organs over time.

Q: What if I accidentally took too much Omnistad?

Official documents advise seeking immediate medical attention or contacting a healthcare professional for guidance in the event of an overdose. Clinical consequences of overdosage have not typically been reported in patients with normal kidney function. If the drug's elimination is delayed due to kidney issues, the contrast medium may be theoretically eliminated via a procedure like hemodialysis.

Q: How long after stopping Omnistad will the medicine be completely out of my system?

Omnistad is eliminated primarily through the kidneys, which is a relatively fast process for the bulk of the dose in patients with healthy kidney function. However, the official documentation mentions that small amounts of gadolinium, the active substance, can be retained for months or years in various body tissues, including the brain and bone.

Q: Can Omnistad affect the results of common lab tests?

Yes, regulatory information indicates that Omnistad can affect the results of some laboratory tests. Transitory changes in serum iron have been observed, and the drug may interfere with methods used to measure calcium, particularly in patients with kidney problems. Patients should inform their medical team if a blood sample is taken on the same day as the examination.

Q: How common are the most frequently reported side effects of Omnistad?

Based on clinical study data reviewed by regulatory bodies, the most frequent adverse reactions reported in adult patients are typically nausea, headache, and dizziness. These specific reactions were observed to occur in 3% or less of the patients studied.

Q: Can Omnistad cause problems with sleeping?

While not listed as a common effect, some patient information leaflets note that drowsiness may occur as an unusual unwanted effect during or after the examination. If you experience unexpected drowsiness, you should discuss it with your healthcare team.

Q: Is it normal to feel a little dizzy when first starting Omnistad?

Official documents list dizziness among the most frequent adverse reactions, although it occurred in a small percentage (3% or less) of patients in clinical studies. If dizziness is experienced after administration, patients should consult their healthcare provider.

Q: Can Omnistad affect my ability to drive or operate machinery?

The official documents do not contain a direct instruction regarding driving. However, because effects such as dizziness and drowsiness have been reported, official guidance suggests that patients who experience these symptoms should consider caution when operating machinery or driving.

Q: How long does it usually take for side effects from Omnistad to go away?

According to patient information, most unwanted effects experienced from the drug are described as mild and of short duration. Patients are advised to contact their doctor if any effects become severe or persist for more than a few days.

Q: Is the long-term evidence for Omnistad's use well-established?

While the drug's immediate effects are established for diagnostic purposes, the FDA requires warnings regarding Gadolinium Retention in organs for months or years. The health consequences related to this long-term retention are still being assessed by regulatory bodies.

Q: Are there certain groups of people for whom Omnistad has limited research data?

Official regulatory labels specifically address the use in certain groups, noting that pregnant and pediatric patients may be at an increased risk of gadolinium staying in the body. Human data for use during pregnancy is currently limited.

Q: Is there an official patient leaflet or package insert for Omnistad I can read?

Yes, regulatory agencies require that a Medication Guide or Patient Medication Information leaflet be provided along with the drug. This document is written to give patients important information on the drug's safe use, warnings, and potential side effects.

Q: What is the typical monitoring schedule (e.g., blood tests) for someone on Omnistad?

The official label recommends screening patients at risk for reduced kidney function before administering the drug. This screening often involves laboratory testing, such as blood tests, to estimate the Glomerular Filtration Rate (GFR), which measures kidney function.

Q: What should I do if a side effect of Omnistad seems serious?

Official documents advise seeking immediate medical attention or contacting a healthcare professional in the event of a serious reaction, such as a severe allergic reaction (anaphylaxis) or symptoms of Nephrogenic Systemic Fibrosis (NSF).

Q: How does Omnistad affect other health conditions I might have, like diabetes or high blood pressure?

The label notes that for patients with pre-existing conditions that affect the kidneys, such as diabetes or hypertension (high blood pressure), an assessment of kidney function (GFR estimated) is required prior to administration due to the risk of NSF.

Q: What is the significance of the medication guide that comes with Omnistad?

The Medication Guide is a patient leaflet mandated by the FDA that provides critical information. It summarizes the most important warnings, the drug's approved uses, and possible side effects to ensure patients understand how to use the drug safely and effectively.

Q: Is Omnistad known to cause any skin reactions or allergies?

Yes, regulatory documents report that Hypersensitivity Reactions (allergic reactions) can occur with Omnistad. These reactions may include skin symptoms such as rash or hives (urticaria), and can occasionally be severe or life-threatening.

Q: Is there a certain age limit for people who can use Omnistad?

Official information indicates that the drug is contraindicated (should not be used) in neonates up to 4 weeks of age due to their immature renal function. Its use is established for children aged 2–16 years for certain procedures.

Q: What resources are available for patients who want more information about Omnistad?

The official label advises that patients can ask their healthcare provider for access to the full official labeling or documentation about the drug, which includes information written both for health professionals and for patients.

The official regulatory guidelines for Omnistad (Gadodiamide) Injection establish mandatory requirements for its storage, handling, and disposal.

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 30 C (below 86 F). Do not freeze.
Protection	Protect from light (store in outer carton).
Integrity Check	Visually inspect for particulate matter or discoloration before use. The solution must not be used if either is present.
Child Safety	Keep the medicine out of the sight and reach of children.

Handling and Disposal

Omnistad is a single-use product, and its stability profile mandates immediate administration.

Requirement	Official Instruction
Post-Opening Stability	Draw into the syringe and use immediately.
Disposal	Any unused portion of the injection must be discarded.
Waste Handling	Dispose of the unused product and all waste materials in accordance with local requirements for pharmaceutical waste.